Thu, Apr 17, 2014, 7:10 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Advanced Cell Technology Inc. Message Board

  • dojothegreat33 dojothegreat33 Oct 10, 2013 3:49 PM Flag

    How Many 2013 Goals Will Be Met?

    Focus and Strategy for 2013

    Our focus and strategy are clear. In 2013 we plan to build on the growing awareness of the promise of regenerative medicine to make it the best year not only in this field but in the company’s history, as well. This year we hope to achieve a number of specific milestones, including:

    Reverse stock split and up-listing of our stock to NASDAQ
    Completion of both of our Phase I trials for Stargardt’s Disease in the U.S. and Europe, and our Phase I trial for dry age-related macular degeneration (dry AMD)
    Sharing final Phase I trial results with our followers
    New developments involving our various initiatives in Europe
    Initiation of our Induced Pluripotent Stem (iPS) Cell-Derived Human Platelet Program
    Initiation of three Phase II trials for SMD and dry AMD
    Initiation of clinical trial for myopia

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ACTC
0.0637+0.0009(+1.43%)Apr 17 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.